Insider Trading Alert - WSM, WST, PDCO, ACT And CTL Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Wednesday, Nov. 27, 2013, 160 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $788.24 to $484,583,953.98.

Highlighted Stocks Traded by Insiders:

Williams-Sonoma (WSM) - FREE Research Report

Connolly Pat who is Evp Cmo at Williams-Sonoma sold 40,000 shares at $58.82 on Nov. 27, 2013. Following this transaction, the Evp Cmo owned 519,859 shares meaning that the stake was reduced by 7.14% with the 40,000 share transaction.

The shares most recently traded at $59.28, up $0.46, or 0.77% since the insider transaction. Historical insider transactions for Williams-Sonoma go as follows:

  • 4-Week # shares sold: 40,000
  • 12-Week # shares sold: 45,445
  • 24-Week # shares sold: 61,804

The average volume for Williams-Sonoma has been 1.2 million shares per day over the past 30 days. Williams-Sonoma has a market cap of $5.7 billion and is part of the services sector and retail industry. Shares are up 35.66% year to date as of the close of trading on Wednesday.

Williams-Sonoma, Inc. operates as a multi-channel specialty retailer of home products. It operates in two segments, Direct-to-Customer and Retail. The stock currently has a dividend yield of 2.09%. The company has a P/E ratio of 60.6. Currently there are 5 analysts that rate Williams-Sonoma a buy, no analysts rate it a sell, and 15 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WSM - FREE

TheStreet Quant Ratings rates Williams-Sonoma as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Williams-Sonoma Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

West Pharmaceutical Services (WST) - FREE Research Report

Morel Donald E Jr who is Chair of the Board & CEO at West Pharmaceutical Services sold 35,000 shares at $48.60 on Nov. 27, 2013. Following this transaction, the Chair of the Board & CEO owned 970,801 shares meaning that the stake was reduced by 3.48% with the 35,000 share transaction.

The shares most recently traded at $49.97, up $1.37, or 2.74% since the insider transaction. Historical insider transactions for West Pharmaceutical Services go as follows:

  • 4-Week # shares sold: 55,302
  • 12-Week # shares sold: 55,302
  • 24-Week # shares sold: 68,485

The average volume for West Pharmaceutical Services has been 251,400 shares per day over the past 30 days. West Pharmaceutical Services has a market cap of $3.5 billion and is part of the health care sector and health services industry. Shares are up 82.94% year to date as of the close of trading on Wednesday.

West Pharmaceutical Services, Inc. manufactures and sells components and systems for injectable drug delivery and plastic packaging, as well as delivery system components for the pharmaceutical, healthcare, and consumer products industries. The stock currently has a dividend yield of 0.8%. The company has a P/E ratio of 32.3. Currently there is 1 analyst that rates West Pharmaceutical Services a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WST - FREE

TheStreet Quant Ratings rates West Pharmaceutical Services as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full West Pharmaceutical Services Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Patterson Companies (PDCO) - FREE Research Report

Gugino Ann B who is Vice President at Patterson Companies sold 1,008 shares at $41.43 on Nov. 27, 2013. Following this transaction, the Vice President owned 32,979 shares meaning that the stake was reduced by 2.97% with the 1,008 share transaction.

The shares most recently traded at $41.38, down $0.05, or 0.13% since the insider transaction. Historical insider transactions for Patterson Companies go as follows:

  • 4-Week # shares sold: 1,008
  • 12-Week # shares sold: 15,839
  • 24-Week # shares sold: 18,960

The average volume for Patterson Companies has been 636,000 shares per day over the past 30 days. Patterson Companies has a market cap of $4.4 billion and is part of the services sector and wholesale industry. Shares are up 20.8% year to date as of the close of trading on Wednesday.

Patterson Companies, Inc. distributes dental, veterinary, and rehabilitation supplies. The stock currently has a dividend yield of 1.55%. The company has a P/E ratio of 20.0. Currently there are 5 analysts that rate Patterson Companies a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PDCO - FREE

TheStreet Quant Ratings rates Patterson Companies as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Patterson Companies Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Actavis (ACT) - FREE Research Report

Mayr Charles M who is Chief Communic Off-Global at Actavis sold 10,000 shares at $162.60 on Nov. 27, 2013. Following this transaction, the Chief Communic Off-Global owned 11,396 shares meaning that the stake was reduced by 46.74% with the 10,000 share transaction.

The shares most recently traded at $145.10, down $17.50, or 12.06% since the insider transaction. Historical insider transactions for Actavis go as follows:

  • 12-Week # shares sold: 6,200
  • 24-Week # shares sold: 145,976

The average volume for Actavis has been 1.1 million shares per day over the past 30 days. Actavis has a market cap of $18.6 billion and is part of the health care sector and drugs industry. Shares are up 62.01% year to date as of the close of trading on Monday.

Actavis plc, an integrated specialty pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally.

Exclusive Offer: Get the latest Stock Analysis on ACT - FREE

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

CenturyLink (CTL) - FREE Research Report

Melville C G Jr who is Director at CenturyLink sold 700 shares at $30.69 on Nov. 27, 2013. Following this transaction, the Director owned 7,238 shares meaning that the stake was reduced by 8.82% with the 700 share transaction.

The shares most recently traded at $30.97, up $0.28, or 0.9% since the insider transaction. Historical insider transactions for CenturyLink go as follows:

  • 4-Week # shares sold: 700
  • 12-Week # shares sold: 700
  • 24-Week # shares sold: 16,113

The average volume for CenturyLink has been 4.8 million shares per day over the past 30 days. CenturyLink has a market cap of $18.2 billion and is part of the technology sector and telecommunications industry. Shares are down 21.47% year to date as of the close of trading on Wednesday.

CenturyLink, Inc. operates as an integrated telecommunications company in the United States. The stock currently has a dividend yield of 7.03%. Currently there are 9 analysts that rate CenturyLink a buy, 2 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CTL - FREE

TheStreet Quant Ratings rates CenturyLink as a hold. Among the primary strengths of the company is its expanding profit margins over time. At the same time, however, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full CenturyLink Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers